Skip directly to content

Referencias


1. MacFarlane LA, Todd DJ. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2014;17(4):359-368.
2. Clark JD, Flanagan ME. Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023-5038.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
4. Tofacitinib for the treatment of rheumatoid arthritis. Advisory committee briefing document. May 9, 2012 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf. Accessed November 20, 2014.
5. Lundquist LM, Cole SW. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop. 2014;5(4):504-511.
6. Zerbini CA, Lomonte AB. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2012;8(4):319-331.
7. Waldburger JM, Firestein GS. Garden of therapeutic delights: new targets in rheumatic diseases. Arthritis Res Ther. 2009;11(1):206. doi:10.1186/ar2556.
8. Cohen MD, Keystone EC. JAK inhibitors for rheumatoid arthritis. Curr Treat Options in Rheum. 2015;1:305-319.
9. Mócsai A, Kovacs L. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12:43.
10. Barclay N, Tarallo M. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. PMS 78. Value Health. 2013;16:A568.
11. XELJANZ Documento local de producto CDSv 16.0 Fecha Efectiva: 26 de enero 2018
12. XELJANZ XR Documento Local de Producto CDSv 8.0


PP-XEL-COL-0388

Este material es de uso exclusivo para el cuerpo médico. ©Pfizer S.A.S. Todos los derechos reservados – Prohibida su reproducción total o parcial sin autorización del titular.

 Volver a menú